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ABSTRACT
Introduction: Current treatments for Alzheimer’s and
other neurodegenerative diseases have only limited
effectiveness meaning that there is an urgent need for
new medications that could influence disease incidence
and progression. We will investigate the potential of a
selection of commonly prescribed drugs, as a more
efficient and cost-effective method of identifying new
drugs for the prevention or treatment of Alzheimer’s
disease, non-Alzheimer’s disease dementias,
Parkinson’s disease and amyotrophic lateral sclerosis.
Our research will focus on drugs used for the
treatment of hypertension, hypercholesterolaemia and
type 2 diabetes, all of which have previously been
identified as potentially cerebroprotective and have
variable levels of preclinical evidence that suggest they
may have beneficial effects for various aspects of
dementia pathology.
Methods and analysis: We will conduct a
hypothesis testing observational cohort study using
data from the Clinical Practice Research Datalink
(CPRD). Our analysis will consider four statistical
methods, which have different approaches for
modelling confounding. These are multivariable
adjusted Cox regression; propensity matched
regression; instrumental variable analysis and
marginal structural models. We will also use an
intention-to-treat analysis, whereby we will define all
exposures based on the first prescription observed in
the database so that the target parameter is
comparable to that estimated by a randomised
controlled trial.
Ethics and dissemination: This protocol has been
approved by the CPRD’s Independent Scientific
Advisory Committee (ISAC). We will publish the
results of the study as open-access peer-reviewed
publications and disseminate findings through
national and international conferences as are
appropriate.
INTRODUCTION
Rationale
Alzheimer’s disease (AD) is a progressive
disease affecting brain function and independ-
ent living and eventually requires full-time
care. There are only a few treatments that tem-
porarily help symptoms such as memory loss;
however, these eventually become ineffective
as the underlying disease progresses unabated.
Part of the difﬁculty of treating AD is that it
involves the activation of many destructive pro-
cesses in the brain, each of which is likely to
need simultaneous treatment if the progres-
sion of the disease is to be halted.
For this reason, there is urgent need for new
evidence about medications that could
Strengths and limitations of this study
▪ This study will involve a large sample of data
and has considerable power to detect even rela-
tively small effects, even under highly conserva-
tive Bonferroni corrections. For example, the
sample to assess the progression of dementia
contains 105 471 patients and has a minimum
detectable HR of 0.931.
▪ We plan to use four different statistical methods
in our analysis, which have different approaches
for modelling confounding. By doing this, we
will be able to assess the merits of each method
in the given situation in order to minimise
confounding.
▪ Dementia is a heterogeneous outcome, and elec-
tronic codes used to define cases in primary
care may not be as accurate as cases in clinical
cohorts. We will undertake sensitivity analyses to
explore how this may affect our results.
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inﬂuence the incidence and progression of AD. One
promising approach is to investigate drug repositioning,1
which offers a time-effective and cost-effective alternative
to traditional drug development. A recent consensus study
of dementia experts identiﬁed a short-list of individual
and classes of prescribed drugs that may be repurposed as
novel treatments for dementia.2 The short-list included
compounds used to treat hypertension, hypercholesterol-
aemia and type 2 diabetes, all of which can be classed as
having ‘cerebroprotective’ properties and have variable
levels of preclinical evidence that suggest they may have
beneﬁcial effects for various aspects of dementia path-
ology. However as yet there is limited pharmacoepidemio-
logical data to support their effects in human populations.
Therefore, we plan to investigate whether these existing
medications could be repurposed to prevent or treat AD.
Furthermore, the overlap of different forms of neuro-
degenerative disease would suggest that there may be
scope to translate existing or newly identiﬁed interven-
tions for testing in neurodegenerative diseases where
similarities exist. Thus, we will start by examining the
most common form of neurodegenerative disease—
AD.3 4 We will then investigate whether the drug candi-
dates could also be repurposed to treat or prevent other
neurodegenerative diseases—these will include other
non-Alzheimer’s disease dementias (NADD) (ie, the
group for dementias in which AD is not thought to play
a part), Parkinson’s disease (PD) and amyotrophic
lateral sclerosis (ALS). Collectively, these ﬁndings will
allow the prioritisation of drugs to be tested as repur-
posed treatments in clinical trials of AD and other neu-
rodegenerative diseases in the future.
Objectives
To investigate whether commonly prescribed medica-
tions, previously identiﬁed as potentially cerebroprotec-
tive, are associated with the incidence or progression of
neurodegenerative disease.
We will focus on the following medications:
A. Treatments for hypertension.
B. Treatments for hypercholesterolaemia.
C. Treatments for type 2 diabetes.
Along with the following neurodegenerative diseases:
A. Alzheimer’s disease (AD).
B. Non-Alzheimer’s disease dementias (NADD).
C. Parkinson’s disease (PD).
D. Amyotrophic lateral sclerosis (ALS).
METHODS AND ANALYSIS
Study design
We will conduct a hypothesis testing observational
cohort study of neurodegenerative disease incidence
and progression, using data from the Clinical Practice
Research Datalink (CPRD).
Participants
We will include men and women older than 40 years,
with at least 12 consecutive months of records classiﬁed
as ‘acceptable’ by the CPRD from all ‘up to standard’
practices.5 Patients registered at a practice <365 days
before their 40th birthday, or those with a ﬁrst record of
one of the index drug classes of interest before their
40th birthday will be excluded. This will ensure high-
quality assessment of baseline data and possible
confounders.
Sample selection
We will investigate the incidence and progression of AD,
NADD, PD and ALS. Our investigations into the inci-
dence will focus on treatments which are reported to be
cerebroprotective and are currently prescribed for
hypertension,6 hypercholesterolaemia7 8 and type 2 dia-
betes.9 For each treatment, we will conduct two analyses.
The ﬁrst will compare treated to untreated individuals
with similar indications—this is cohort A. The second
will compare the outcomes of individuals given different
subclasses of speciﬁc medications—this is cohort B. We
will also investigate progression using a third cohort,
cohort C. Progression will be deﬁned as the postdiagno-
sis survival of a patient. For each neurodegenerative
disease group of interest, we will determine the effects
on progression of the three possible new treatments. In
cohort C, exposure will be deﬁned in two ways: (1) using
patients being prescribed these drugs at the time of
diagnosis of their neurodegenerative disease; and (2)
using those issued new prescriptions postdiagnosis. The
structure of these three cohorts is summarised in table 1
and further explained in the text that follows. All of the
cohorts rely on deﬁned diagnoses and exposures, which
are recorded in the CPRD through the use of Read and
product codes, respectively. Read codes uniquely identify
clinical terms recorded by the general practitioner (GP)
during a consultation, while product codes uniquely
identify prescriptions issued. Both types of code are
recorded with a date, and this will be used to determine
the dates of diagnosis and exposure required to deﬁne
the cohorts.
Cohort A
For each treatment, we will create a cohort of patients
who are diagnosed with the condition the treatment is
used for or ‘at risk’ of that condition. This will be deter-
mined by the indications and test results described in
table 2. We will split each cohort into ‘exposed’ and
‘unexposed’ groups. The ‘exposed’ group will consist of
patients who received a treatment of interest within
6 months of initial diagnosis of the condition for which
the treatment is being given (the ‘indication’ for treat-
ment). The ‘unexposed’ group will consist of all others
in the cohort. Patients will be identiﬁed as having
received a treatment of interest by product codes (see
online supplementary ﬁles 1–3). Therefore, in this ana-
lysis, we will compare an ‘exposed’ group of individuals
who were prescribed the treatment to an ‘unexposed’
group of individuals who received similar test results (ie,
were ‘at risk’ of or diagnosed with the indication for
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treatment), but did not receive the treatment, as illu-
strated in ﬁgure 1. The aim of this approach is to
address confounding by indication that could cause bias
if the ‘unexposed’ group is drawn from the full popula-
tion, whom are likely to be healthier. It will also allow us
to minimise excluded immortal time bias as patients will
be followed from a consistent index date (date ﬁrst at
risk or date of ﬁrst diagnosis of the condition itself if
there was no preceding period at risk).
Follow-up for cohort A will start on the ﬁrst date a
patient is diagnosed with the condition the treatment is
used for or ‘at risk’ of that condition (see table 2 and
online supplementary ﬁles 1–3.) Follow-up will end with
the earliest of a relevant neurodegenerative disease diag-
nosis, death or censoring due to the end of registration
at a CPRD general practice.
Cohort B
In this analysis, we will compare different drug subclasses
that exist for a given treatment (listed in box 1). To do
this, we will create a cohort of all patients who were pre-
scribed a treatment and categorise them by the drug
subclass they initially received. This will allow us to
compare the outcomes for each of the resulting sub-
groups. For each treatment, we have deﬁned the most
frequently prescribed subclass as the control (indicated
in box 1). In the primary analysis of this cohort, we will
exclude patients initially prescribed the control subclass
if they receive another subclass of the same treatment at
the same time, however we do not expect this to be a
common. We will explore the outcomes of individuals
prescribed multiple subclasses, other than that speciﬁed
above, in a sensitivity analysis.
Follow-up for cohort B will start on the date of ﬁrst eli-
gible prescription as determined by a product code (see
the treatment code lists in online supplementary ﬁles 1–3).
Follow-up will end with the earliest of a relevant neurode-
generative disease diagnosis, death or censoring due to the
end of registration at a CPRD general practice.
Cohort C
For each neurodegenerative disease group of interest,
we will create a cohort of individuals with a read code
indicating this outcome (see online supplementary ﬁle
4) or a product code indicating they received treatment
for the outcome (see online supplementary ﬁle 5).
These cohorts will be used to investigate the associations
of neurodegenerative disease progression with exposure
to one of the three treatment groups of interest: treat-
ments for hypertension, treatments for hypercholesterol-
aemia and treatments for type 2 diabetes. We will
investigate both exposure before and after the diagnosis
of a neurodegenerative disease. For all of the treatments
we consider, each cohort will be split into ‘exposed’ and
Table 1 Comparison of the three cohort types
Cohort A Cohort B Cohort C
Purpose To investigate incidence by
comparing treated and untreated
individuals.
To investigate incidence by
comparing the different drug
subclasses of each treatment.
To investigate progression by
comparing treated and untreated
individuals.
Number of
cohorts
required
There will be three cohorts of this
type, one for each treatment of
interest.
There will be three cohorts of this
type, one for each treatment of
interest.
There will be three cohorts of
this type, one for each of
dementia (AD or NADD), PD
and ALS.
Exposures Treatments for hypertension,
hypercholesterolaemia and type 2
diabetes.
Treatments for hypertension,
hypercholesterolaemia and type 2
diabetes.
Treatments for hypertension,
hypercholesterolaemia, and type
2 diabetes.
Start of
follow-up
(index date)
Date at first risk of the condition the
treatment is used for or date of first
diagnosis of the condition itself if
there was no preceding period ‘at
risk’.
Date of first prescription of a
treatment of interest.
Date of first diagnosis of
neurodegenerative disease of
interest.
Outcome Diagnosis of neurodegenerative
disease of interest.
Diagnosis of neurodegenerative
disease of interest.
Death.
Exclusion
criteria
Individuals with <12 consecutive
months of records prior to cohort
entry.
Individuals prescribed treatment and
control medications at the same
time or with <12 consecutive
months of records prior to cohort
entry.
Individuals with <12 consecutive
months of records prior to cohort
entry.
Statistical
analysis
Conventional regression, propensity
score regression, instrumental
variable analysis and marginal
structural models.
Conventional regression, propensity
score regression, instrumental
variable analysis and marginal
structural models.
Conventional regression,
propensity score regression and
marginal structural models.
AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; NADD, Non-Alzheimer’s disease dementias; PD, Parkinson’s disease.
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‘unexposed’ groups. In the analysis, individuals in the
‘exposed’ group, that is, those who were prescribed the
treatment under investigation, will be compared with
individuals in the ‘unexposed’ groups, that is, those who
did not receive the treatment.
Follow-up for cohort C will start with the ﬁrst recorded
read code indicating AD or other neurodegenerative
disease (see online supplementary ﬁle 4) or, in the
absence of a diagnosis, the ﬁrst recorded product code
indicating they received treatment for a neurodegenera-
tive disease (see online supplementary ﬁle 5). Follow-up
will end with the earliest of death or censoring due to the
end of registration at a CPRD general practice.
Variables
Exposures
For our primary analysis, we will deﬁne all exposures
based on the ﬁrst prescription observed in the data-
base.10 This is so that the target parameter estimated in
the observational study will be comparable to that
estimated by a randomised controlled trial (RCT).
Analogous to an intention-to-treat analysis in a RCT,
patients initially prescribed an active treatment medica-
tion (exposed), but later stop that medication or switch
to a control drug (unexposed), will be allocated to treat-
ment (ie, classiﬁed as exposed, irrespective of what
happens in the future) and vice versa. First time pre-
scriptions of the medications of interest (treatment and
control) will be deﬁned as people who received at least
one prescription of the product but who had no use of
a related product during the 12 months before the start
of follow-up. The prescriptions will be identiﬁed using
product codes recorded in the therapy ﬁle in the CPRD,
which details the date each prescription was issued, the
quantity of drug prescribed and the dosage. Patients ini-
tially receiving more than one prescription of a drug of
interest will be included in our analysis in a group repre-
senting the speciﬁc combination of drugs they receive.
The effects of treatment switching and disease control
will be explored using marginal structural models. We
will also consider disease severity for the treatment indi-
cations through the use of instrumental variable analysis.
Table 2 The cohorts of type A, one for each treatment of interest
Cohort Entry criteria
Treatments for hypertension Patients who are ‘at risk’ of hypertension as indicated by one of the following:
▸ Medical code indicating a diagnosis of ‘at risk’ of hypertension.
▸ Recorded systolic blood pressure test result between 120 and 139 mm Hg.
▸ Recorded diastolic blood pressure test result between 80 and 89 mm Hg.
In the case of no period ‘at risk’, patients who have hypertension as indicated by one of the
following:
▸ Medical code indicating a diagnosis of hypertension.
▸ Product code indicating treatment for hypertension.
▸ Recorded systolic blood pressure test result of 140 mm Hg or more.
▸ Recorded diastolic blood pressure test result of 90 mm Hg or more.
See online supplementary file 1 for code lists relating to hypertension.
Treatments for
hypercholesterolaemia
Patients who are ‘at risk’ of hypercholesterolaemia as indicated by one of the following:
▸ Medical code indicating a diagnosis of ‘at risk’ of hypercholesterolaemia.
▸ Recorded test result where total cholesterol level is between 4 and 5 mmol/L.
▸ Recorded test result where LDL cholesterol level is between 2 and 3 mmol/L.
In the case of no period ‘at risk’, patients who have hypercholesterolaemia as indicated by
one of the following:
▸ Medical code indicating a diagnosis of hypercholesterolaemia.
▸ Product code indicating treatment for hypercholesterolaemia.
▸ Recorded test result where total cholesterol level exceeds 5 mmol/L.
▸ Recorded test result where LDL cholesterol level exceeds 3 mmol/L.
See online supplementary file 2 for code lists relating to hypercholesterolaemia.
Treatments for type 2 diabetes Patients who are ‘at risk’ of type 2 diabetes as indicated by a medical code. In the case of
no period ‘at risk’, patients who have type 2 diabetes as indicated by one of the following:
▸ Medical code indicating a diagnosis of type 2 diabetes.
▸ Product code indicating treatment for type 2 diabetes.
▸ Medical code indicating a diagnosis of unspecified diabetes, first received over the age
of 40.
▸ Product code indicating treatment with insulin, first received over the age of 40.
This assumes that patients treated with insulin or receiving a diagnosis of unspecified
diabetes after the age of 40 have type 2 diabetes. Patients with a recorded diagnosis of
type 1 diabetes at any age will be excluded. See online supplementary file 3 for code lists
relating to type 2 diabetes.
LDL, low density lipoprotein.
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Outcomes
For incidence, we will identify the neurodegenerative
disease outcomes (AD, NADD, PD and ALS) by the ﬁrst
record of a relevant read code (see online
supplementary ﬁle 4) or the ﬁrst record of a product
code indicating treatment for the neurodegenerative
disease (see online supplementary ﬁle 5). For incidence
and progression, we will identify deaths using linked
Ofﬁce of National Statistics (ONS) data.
Covariates
We will match all covariates on date of birth, sex, year
of index date and years of recorded history in the
database before the index date. The covariates we will
include in our analyses are body mass index, smoking
status, alcohol consumption, a postcode-based measure
of socioeconomic position, previous history of
coronary-artery disease, previous coronary-bypass surgery
and cerebrovascular disease including stroke. We will also
control for other major chronic illness (including cancer,
arthritis) using the Charlson Index11 12 and for consult-
ation rate, calculated by dividing the total number of
clinic visits prior to the index date by the length of each
patient’s follow-up. If there are missing data in the covari-
ates, we will consider using multiple imputation.
Unfortunately not all covariates of interest, such as exer-
cise, are recorded within the CPRD, and this may lead to
unmeasured confounding. We hope to minimise this con-
founding by using methods, such as instrumental variable
analysis, which can account for it to some degree.
Data sources
The main data source for this project is the CPRD.
Cause-speciﬁc mortality from linked ONS data is more
accurate than CPRD data on mortality from general
practices.13 Therefore, we will use the ONS data to iden-
tify date and cause of death and test our hypotheses
relating to mortality using data from linked practices
only. We will also be using the Index of Multiple
Deprivation (IMD) in order to deﬁne socioeconomic
position, which is listed as a covariate in our analysis.
Study size
table 3 details the expected number of events for the event
used to deﬁne the start of follow-up with the minimum
sample size and detectable HR (α=0.05, β=0.80) for the
Figure 1 The cohort construction for cohort type A, designed to eliminate immortal time bias. A patient will enter the cohort for a
given treatment when they first become ‘at risk’ of the condition the treatment is used for or, in the case of no period ‘at risk’,
when they are first diagnosed with the condition (see table 2). For example, when they are diagnosed as at ‘at risk of’
hypertension or, in the case of no period ‘at risk’, when they receive a diagnosis of hypertension. We define cohort entry in this
way to avoid excluded immortal time bias that can occur when cohort entry is determined by treatment variation over time.33 34
Immortal time is the period during follow-up when the outcome cannot occur. Consider the hypertension example above,
suppose we started following the treated patients in our cohort from the date of their first prescription of a treatment for
hypertension and the untreated patients from a matched date. This would make it impossible for the treated patients to have an
outcome, such as dementia, prior to their first prescription. Consequently, patients in this group would all have a period before
treatment, when they could not be diagnosed with dementia, that is, they could not experience the outcome. This period is their
immortal time, and it must be correctly attributed to the ‘unexposed’ group so that their outcome is not falsely attributed to their
exposure. To do this, patients in the ‘exposed’ and ‘unexposed’ groups must be followed-up and compared from the same start
date. In this cohort, we are minimising excluded immortal time by following patients from either a test result or diagnosis where
possible. In order to capture all relevant patients, we will allow those receiving treatment without a recorded diagnosis to be
included as it is assumed treatment suggests a diagnosis.
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Cox regression analysis of cohorts B and C. The minimum
detectable HR is taken to be the detectable HR for the
smallest exposed group tested against the control group.
The minimum sample size is the sum of patients in the
smallest exposed group and the control group. It is difﬁ-
cult to provide such details for cohort A due to its novel
design that includes patients who are ‘at risk’ of the condi-
tion the treatment is used for. We can however consider
the expected number of events listed for cohort B to be
conservative estimates for the sample size of cohort A as all
patients receiving treatment are included in cohort A by
deﬁnition. This study will involve a large sample of data
and has considerable power to detect even relatively small
effects. Therefore, our statistical power will be more than
adequate to test all of our proposed hypotheses, even
under highly conservative Bonferroni corrections. Further
details concerning the sample size and detectable HRs
(α=0.05, β=0.80) for speciﬁc comparisons within cohorts B
and C can be found in online supplementary ﬁles 6 and 7.
Further details concerning the expected number of
events, including at the drug subclass level, can be found
in online supplementary ﬁle 8.
Bias
There are three main sources of bias in our results:
ascertainment bias, collider bias and immortal time bias.
To overcome ascertainment bias, we will control for con-
sultation rate in our analyses because people who have
more chronic conditions such as hypertension, diabetes
or renal insufﬁciency may have higher rates of consult-
ation, which may also increase the opportunity for
recording other diagnoses such as dementia. Collider
bias could occur if we conditioned on events that hap-
pened as a result of the prescription the patient was
issued. To prevent this form of bias from affecting our
results, we will deﬁne each covariate using data inputted
prior to the index date.14 Finally, we will minimise the
risk of immortal time bias in two ways. First, to prevent
misclassiﬁed immortal time, we will deﬁne exposures
based on the ﬁrst prescription observed in the data-
base10 and use an intention-to-treat analysis. Second, to
minimise immortal time, we will follow-up patients
(exposed and unexposed) from a consistent index date.
This will be a test result or a read code indicating diag-
nosis where possible;15 however, to capture all relevant
patients, we will allow those receiving treatment without
a recorded diagnosis to be included.
Confounding
We have identiﬁed two key sources of confounding in
our study: confounding by indication and time-
dependent confounding. To address the former, we will
use four different statistical methods, which have differ-
ent approaches for modelling confounding. Through
examination of these approaches, we hope to highlight
any uncontrolled confounding that may be leading to
false conclusions about drug effect. We will also account
for confounding by indication in the construction of
our cohorts. Consider cohort A, where we compare
‘exposed’ and ‘unexposed’ groups of individuals.
Drawing the ‘unexposed’ group from the full population
can introduce bias as they are likely to be in better
health. We will avoid this by deﬁning cohort entry on
the basis of ﬁrst test or recording of a relevant read
code so the ‘exposed’ and ‘unexposed’ groups will have
more in common. In addition to this, we will address
time-dependent confounding in our study. This will be
carried out using marginal structural models, which can
allow for time-dependent confounding and treatment
switching between products.
Missing data
We will automatically use multiple imputation if there
are missing data, as we are aware that a small amount of
missing data across multiple variables could result in a
large number of incomplete cases and consequently
limit the sample for a complete case analysis. We will
conduct sensitivity analyses to investigate the effect of
imputing these missing data on our results.16–18
Multiple testing
We will account for multiple testing using permutation
analysis where appropriate. A portion of the data
included in this project was previously used in a study
investigating the association of α-adrenoceptor blocking
drugs and angiotensin-II receptor antagonists with AD
and non-AD dementias.19 We anticipate the overlap
between our study and this previous study to be around
4% for each of cohorts A and B and 9% for cohort
C. The authors acknowledge that this might be a
Box 1 The drug subclasses of interest for each treatment
group with the control treatments indicated
Treatments for hypertension
▸ Beta-adrenoceptor blocking drugs (control)
▸ Angiotensin-converting enzyme inhibitors
▸ Thiazides and related diuretics
▸ Calcium channel blockers
▸ Loop diuretics
▸ Alpha-adrenoceptor blocking drugs
▸ Centrally acting antihypertensive drugs
▸ Angiotensin-II receptor antagonists
▸ Vasodilator antihypertensive drugs
▸ Potassium-sparing diuretics and aldosterone antagonists
Treatments for hypercholesterolaemia
▸ Statins (control)
▸ Fibrates
▸ Bile acid sequestrants
▸ Omega-3 fatty acid compounds
▸ Ezetimibe
▸ Nicotinic acid group
Treatments for type 2 diabetes
▸ Biguanides (control)
▸ Sulphonylureas
▸ Other antidiabetic drugs
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concern for multiple testing, however wish to highlight
that the analyses conducted in this study will differ from
those used before.
Statistical methods
We will use four statistical approaches in our study—they
are multivariable adjusted Cox regression, propensity
matched regression, instrumental variable analysis and
marginal structural models. We are committed to pre-
senting the ﬁndings from all our analyses, irrespective of
the direction of ﬁndings and will handle discrepancies
between them by assessing the merits of each method in
the given situation. If we discover large main effects of
speciﬁc medications, we may investigate interactions
between covariates and will seek to replicate any interac-
tions in other large samples.
We will be using an intention to treat analysis in our
primary analysis. The reasons for this are twofold. First,
while there are theoretical statistical models for estimat-
ing the effects of treatment switching such as marginal
structural models, these methods require the strong
assumption that there are no unmeasured confounders.
Second, to the best of our knowledge there are no
instrumental variable methods for estimating the effects
of treatment switching. We will investigate treatment
switching using marginal structural models in a second-
ary analysis. All of the methods we will use for this study
are summarised below.
Multivariable adjusted Cox regression
In our ﬁrst analyses, a conventional observational ana-
lysis, we will estimate the HRs of incidence and survival
using Cox proportional hazards models. Both analyses
will use the actual prescriptions issued to the patients.20
We will report these associations adjusted for basic con-
founders (age and gender) and results adjusted for all
measured covariates described previously. We will also
perform tests of the proportional hazards assumption.
Propensity matched regression
In our second analysis, we will construct a sample of
patients balanced on covariates and risk factors using a
propensity score.21–24 We will construct propensity scores
using a logistic regression of the actual treatment
received on the covariates described above. Therefore,
each participant’s propensity score will be their condi-
tional probability (odds) of receiving treatment or not
(cohort types A and C), or receiving treatment versus
control therapy (cohort type B). We will match each
patient receiving one treatment to another patient
receiving the control treatment with the closest propen-
sity score on a ratio of 1:1 using a nearest neighbour
algorithm with no replacement, and matching will be
restricted to the common support region. Patients
outside the common support region are those pre-
scribed the treatment therapy with propensity scores
higher than any patient prescribed the control treat-
ment and vice versa. We will estimate odds ratios and
HRs of the outcomes using the propensity score
matched sample using logistic and Cox regressions.
Instrumental variable analysis
In our third analysis, we will estimate the effects: (1) treat-
ment or no treatment and (2) the speciﬁc subclass of
medication prescribed, using physicians’ prescribing pre-
ferences as instruments for the prescriptions the GPs
issue to their patients. We cannot directly measure the
physicians’ preferences; therefore, we will use the pre-
scriptions they issued to their previous patients as a proxy
for their preferences. For example, if the instrument
were based on just one previous prescription, physicians
who previously prescribed the treatment therapy would
be categorised as a ‘treatment prescriber’ otherwise they
would be categorised as a ‘control prescriber’. As with
our previous studies we will use seven prior prescriptions
to improve the strength of the instruments.25–27 Using
multiple prior prescriptions will maximise power. We will
report risk differences in the outcomes using additive
structural mean models estimated via the generalised
method of moments.28–30 We will categorise each of the
adverse event outcomes as occurring within 3, 6, 9, 12, 24
and 48 months of index date. Methods for estimating sur-
vival models using instrumental variables are not well
developed. Therefore, we will explore potential in-
strumental variable survival models in a secondary
analysis.31
Marginal structural models
In our fourth analysis, we will estimate the effects of
each treatment using marginal structural models.32 We
Table 3 The expected number of events for the event used to define the start of follow-up presented with the minimum
sample size and detectable HR (α=0.05, β=0.80) for the Cox regression analysis of cohorts B and C
Cohort Start of follow-up
Expected number
of events
Minimum sample
size
Minimum detectable
HR
B Treatment for hypertension 1 018 519 269 808 0.968
Treatment for hypercholesterolaemia 808 687 788 479 0.844
Treatment for type 2 diabetes 200 800 158 775 0.943
C Diagnosis of dementia (AD and NADD) 105 471 105 471 0.931
Diagnosis of PD 20 686 20 686 0.870
Diagnosis of ALS 2227 2227 0.600
AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; NADD, Non-Alzheimer’s disease dementias.
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will use these models to account for time-dependent
confounding and treatment switching. We will construct
inverse probability weights for each treatment based on
the patients’ observed characteristics such as gender,
age, comorbidities and concurrent treatments. We will
use these models to estimate the odds and HRs of
disease incidence and progression.
DISSEMINATION
We will publish the results of the study as open-access
peer-reviewed publications. We will disseminate ﬁndings
through national and international conferences as are
appropriate. Depending on the ﬁndings, we would also
explore additional options for focussed dissemination
within appropriate communities, for example, via an
Alzheimer’s Society dissemination grant.
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